昨日，记者从中国医药保健品进出口商会(以下简称“医保商会”)获悉，今年前10个月，我国医药产品出口391.34亿美元，出口增速比去年同期大幅下降了28个百分点。

yesterday,Reporters from China medical health products import and export chamber of commerce(Hereinafter referred to as"Health-care chamber of commerce")learn,In the first ten months,Our country medicine products are exported to $39.134 billion,Export growth than the same period last year dropped substantially by 28%.

　　医保商会相关负责人指出，导致医药产品出现增幅萎缩的原因很多，其中包括国际市场需求不振的影响，同时药企生产成本上升使竞争力下降，此外国际贸易摩擦日益加重，以及国内监管环境趋严等均增加了我国医药外贸发展的难度。

Health care is pointed out that the relevant person in charge of the chamber of commerce,Lead to pharmaceutical products appear increase atrophy for many reasons,Including the international market demand of influence,At the same time medicine enterprise production costs rise make less competitive,In addition the international trade friction increasingly heavier,And domestic regulatory environment borrowing rules are increased the difficulty of our country medicine foreign trade development.

　　事实上，此前，医保商会就曾警示，2012年是中国医药外贸面临较大困难的一年。在中国医药产品的主要国际市场均增长乏力之时，国内环保标准提高，原材料、劳动力等成本仍有增长的趋势，继续推高中国医药产品的成本，使中国医药产品出口陷入两难境地。不过，医保商会也强调，虽然中国医药产品出口形势不容乐观，但由于医药产品的刚性需求和中国医药产品在国际市场的地位短期无人替代，预计中国医药产品出口仍将保持增长，但增幅将有可能回落到10%-15%之间。

In fact,after,Medical insurance chamber of commerce has warning,2012 is the Chinese medicine trade confronted with difficult years.In China the main pharmaceutical products in the international market are the weak growth,To improve the domestic environmental protection standard,Raw materials/Such as labor cost still has the trend of growth,Continue to push up the cost of China's pharmaceutical products,China's pharmaceutical products export into a dilemma.but,Medical insurance chamber is also emphasized,Although the Chinese pharmaceutical products export situation is not optimistic,But because of pharmaceutical products rigid demand and Chinese medicine products in the international market position short-term no alternative,China is expected to pharmaceutical products export growth will remain,But the growth will likely fall to 10% - 15% between.

　　北京康派特医药经济技术研究中心主任李磊告诉记者，“红火的国内市场足以让药企拥有良好的‘钱景’，所以，接下来医药企业将很可能加码国内市场”。

Beijing kang pat medicine economic technology research center director li lei told reporters,"The domestic market is enough to make medicine enterprises have a good‘QianJing’,so,The medical enterprise will likely pyramid in the domestic market".